Oppenheimer Maintains Outperform on Wave Life Sciences, Lowers Price Target to $29
Benzinga Newsdesk 2 days ago
Analyst RatingsNewsPrice Target
Oppenheimer analyst Cheng Li maintains Wave Life Sciences (NASDAQ:WVE) with a Outperform and lowers the price target from $32 to $29.
Oppenheimer analyst Cheng Li maintains Wave Life Sciences (NASDAQ:WVE) with a Outperform and lowers the price target from $32 to $29.